Latest Outlook : Global Biochips Market Insights, Forecast 2019 to 2025

ResearchMoz presents professional and in-depth study of "Global Biochips Market Insights, Forecast to 2025".

Biochips are bio-microsystems. Bio-microsystems are small integrated devices used for biochemical reactions, biological monitoring, research, academic studies, drug discovery, and much more. In simple terms, biochips are small sized chips that can perform multiple (generally thousands) biochemical reactions parallelly.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2040571

A collection of microarrays or micro-test sites form these biochips. Microarrays when arranged on a surface made up of either glass or silicon, can perform large numbers of tests at the same. Thus, they help in cost and time saving.
North America accounted for the largest share of the biochips market in 2017. The large share of this regional segment can majorly be attributed to the rising geriatric population; increasing prevalence of lifestyle diseases, such as diabetes, asthma, and cardiac disorders; growing adoption of biochips; and a significant number of ongoing research activities and discoveries related to biochips in the North American region. In addition, major local companies have easy access to Biochips market, which makes it the largest and most significant market for suppliers. Asia-Pacific, on the other hand, is expected to grow at the highest CAGR over the next five years.
The global Biochips market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biochips market based on company, product type, end user and key regions.

This report studies the global market size of Biochips in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biochips in these regions.
This research report categorizes the global Biochips market by top players/brands, region, type and end user. This report also studies the global Biochips market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Abbott
Agilent Technologies
Illumina
PerkinElmer
Thermo Fisher Scientific
BioChain
Bio-Rad Laboratories
Cepheid
EMD Millipore
Fluidigm
SuperBioChips Laboratories
US Biomax
Roche Diagnostics

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-biochips-market-insights-forecast-to-2025-report.html/toc

Market size by Product
DNA Chip
Lab-on-a-Chip
Protein Chip
Others
Market size by End User
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostics Centers
Academic & Research Institutes
Other End Users

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Biochips market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Biochips market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Biochips companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Biochips submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Biochips are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2040571

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biochips market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Market Development : Global Insulin Delivery Devices Market Insights, Forecast 2019 to 2025

ResearchMoz presents professional and in-depth study of "Global Insulin Delivery Devices Market Insights, Forecast to 2025".

Insulin Delivery Devices include syringes, pens, pumps, and others. The cost of syringes and insulin pens is low, which enables users to opt for them as first choice devices. High cost of insulin pumps and insulin jet injectors poses a challenge to the growth of the market. Insulin pumps and jet injectors also require special care and maintenance, which is an additional cost burden to patients.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2040700

In 2017, the insulin pens segment accounted for the largest share of the global insulin delivery devices market. The insulin pens segment is further divided into reusable pens and disposable pens.
On the basis of end user, the patients/homecare segment commanded the largest share of the insulin delivery devices market in 2017, and is expected to grow at the highest CAGR during the forecast period.
In 2017, North America accounted for the largest share of the global insulin delivery devices market. The large share of this segment can be attributed to the rising prevalence of diabetes and favorable reimbursement scenario in the U.S. and Canada, growing venture capital investments and issuance of IPOs in the U.S., and FDA approvals to increase the commercial availability of insulin delivery devices in the U.S.
The global Insulin Delivery Devices market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Insulin Delivery Devices market based on company, product type, end user and key regions.

This report studies the global market size of Insulin Delivery Devices in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Insulin Delivery Devices in these regions.
This research report categorizes the global Insulin Delivery Devices market by top players/brands, region, type and end user. This report also studies the global Insulin Delivery Devices market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novo Nordisk
Sanofi
BD
Eli Lilly
Medtronic
Animas
Beta Bionics
Cellnovo
Copernicus
Dance Biopharm
Debiotech
Insulet
MannKind
Owen Mumford
Roche
SOOIL
Tandem Diabetes Care
Valeritas
West Pharma
Ypsomed

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-insulin-delivery-devices-market-insights-forecast-to-2025-report.html/toc

Market size by Product
Insulin Pens
Insulin Pumps
Insulin Syringes
Others
Market size by End User
Patients/Homecare
Hospitals & Clinics

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Insulin Delivery Devices market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Insulin Delivery Devices market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Insulin Delivery Devices companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Insulin Delivery Devices submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Insulin Delivery Devices are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2040700

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Insulin Delivery Devices market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Latest Research : Global Patient Positioning System Market Insights, Forecast 2019 to 2025

ResearchMoz presents professional and in-depth study of "Global Patient Positioning System Market Insights, Forecast to 2025".

Patient positioning systems are the patient handling devices used to keep the patient in a required position or to immobilize the patient during surgery. These devices also used during the cancer therapy/ radiation therapy or precision therapy.
In 2017, the hospital segment accounted for the largest share of the market. This is because all types of surgeries, including cardiac, head & neck, bariatric, thoracic, gynecological, and orthopedic surgeries, are widely performed in hospitals.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2040718

In addition, growth in public healthcare awareness and increasing affordability of treatments are the major factors supporting the growth of the market for hospitals, particularly in developing countries.
The market is dominated by North America, followed by Europe, however, the Asian region is expected to witness the highest growth during the forecast period. The presence of emerging economies like China and India; large population and rising prevalence of chronic diseases ; improving standards of living; and growing demand for quality medical care are some of the key factors driving the high growth of this regional segment.
The global Patient Positioning System market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Patient Positioning System market based on company, product type, end user and key regions.

This report studies the global market size of Patient Positioning System in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Patient Positioning System in these regions.
This research report categorizes the global Patient Positioning System market by top players/brands, region, type and end user. This report also studies the global Patient Positioning System market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Stryker
Getinge
Hill-Rom Holdings
Span-America Medical Systems
C-Rad
Elekta
Smith & Nephew
Merivaara
Leoni
Steris
Mizuho
Famed Zywiec
Orfit Industries

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-patient-positioning-system-market-insights-forecast-to-2025-report.html/toc

Market size by Product
Tables
Surgical Tables
Radiolucent Imaging Tables
Examination Tables
Others
Market size by End User
Hospitals
Ambulatory Surgery Centers
Diagnostic Laboratories
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Patient Positioning System market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Patient Positioning System market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Patient Positioning System companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Patient Positioning System submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Patient Positioning System are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2040718

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Patient Positioning System market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Market Progress : Cleanroom Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 - 2026

ResearchMoz presents professional and in-depth study of "Cleanroom Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026".

Global Cleanroom Consumables Market: Overview

Cleanrooms are controlled environments with low levels of pollutants such as dust, microorganisms, and chemical vapors. Cleanrooms are used in a number of industrial processes, where pollutants can interfere and deteriorate the quality of production. However, complex and varied cleanroom regulations and increase in raw material prices are projected hamper the growth of the global cleanroom consumables market in the near future.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=718459

The global cleanroom consumables market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product, application, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global cleanroom consumables market.

Global Cleanroom Consumables Market: Key Segments

Based on product, the global cleanroom consumables market has been classified into cleanroom apparels, cleaning products, cleanroom stationery, wipers, gloves, and adhesive mats. The cleanroom apparels segment has been divided into coveralls, frocks, boot covers, shoe covers, bouffants, sleeves, pants, face masks, and hoods. The cleaning products segment has been categorized into cleanroom mops, buckets, wringers, and squeegees; validation swabs, and cleaning chemicals. The cleanroom stationery segment has been classified into papers, notebooks and adhesive pads, binders and clipboards, and labels. The wipers segment has been bifurcated into dry and wet. In terms of application, the global cleanroom consumables market has been divided into electronics, pharmaceutical and biotechnology, aerospace and defense, academics and automotive, medical devices, and others. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 and 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Cleanroom Consumables Market: Regional Outlook

Geographically, the global cleanroom consumables market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Malaysia, Thailand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa and GCC Countries). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/cleanroom-consumables-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html/toc

Companies Mentioned in Report

The report also profiles the major players in the market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the global market are Berkshire Corporation, Cantel Medical, Contec, Inc., KCWW, DuPont, KM, Micronclean, Ansell, Texwipe, Thermo Fisher Scientific Inc., and Valutek.

The global cleanroom consumables market has been segmented as follows:

Global Cleanroom Consumables Market, by Product

    Cleanroom Apparels
        Coveralls
        Frocks
        Boot Covers
        Shoe Covers
        Bouffants
        Sleeves
        Pants, Face Masks, and Hoods
    Cleaning Products
        Cleanroom Mops
        Buckets, Wringers, and Squeegees
        Validation Swabs
        Cleaning Chemicals
    Cleanroom Stationery
        Papers
        Notebooks and Adhesive Pads
        Binders and Clipboards
        Labels
    Wipers
        Dry
        Wet
    Gloves
    Adhesive Mats

Global Cleanroom Consumables Market, by Application

    Electronics
    Pharmaceutical and Biotechnology
    Aerospace and Defense
    Academics and Automotive
    Medical Devices
    Others

Global Cleanroom Consumables Market, by Region

    North America
        U.S.
        Canada

    Europe
        Germany
        U.K.
        France
        Spain
        Italy
        Rest of Europe

    Asia Pacific
        China
        Japan
        India
        Malaysia
        Thailand
        Rest of Asia Pacific

    Latin America
        Brazil
        Mexico
        Rest of Latin America

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=718459

    Middle East & Africa
        South Africa
        GCC Countries
        Rest of Middle East & Africa

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Depth Research : Industrial Touchscreen Display Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 - 2026

ResearchMoz presents professional and in-depth study of "Industrial Touchscreen Display Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026".

Global Industrial Touchscreen Display Market: Overview

This comprehensive report by Transparency Market Research analyzes and forecasts the industrial touchscreen display market at the global and regional levels. The report provides analysis for the period from 2016 to 2026, wherein 2018–2026 is the forecast period and 2017 is the base year.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2080995

An in-depth and unbiased market assessment has been made to provide readers with in-depth and accurate analysis. The report emphasizes all major trends anticipated to be witnessed in the industrial touchscreen display market from 2018 to 2026. It also focuses on market drivers, restraining factors, and opportunities for the industrial touchscreen display market during the forecast period. The study provides a complete perspective on the industrial touchscreen display market in terms of value (US$ Mn) and volume (thousand units) across various geographies including North America, Europe, Asia Pacific, Middle East & Africa (MEA), and South America.

The report includes detailed value chain analysis, which is focused on providing an extensive view of the global industrial touchscreen display market. Porter’s five forces analysis has also been provided to help understand the competition scenario of the market. The study incorporates market attractiveness analysis, wherein touchscreen type, component, and end-use industry segments of the market have been benchmarked based on their market size, growth rate, and attractiveness. In order to give complete analysis of the competition scenario in the global industrial touchscreen display market, every geographic region mentioned in the report has been provided with attractiveness analysis.

The market overview chapter of the report on the industrial touchscreen display market explains market trends and dynamics including market drivers, restraining factors, and the current and future opportunities for the industrial touchscreen display market. Market outlook analysis for the global market has also been provided in the report. Additionally, the report offers analysis of different business strategies being adopted by leading players operating in the global industrial touchscreen display market. The market introduction chapter assists in getting an idea of different trends in the industrial touchscreen display market.

Global Industrial Touchscreen Display Market: Scope of Report

The study provides a decisive view on the global industrial touchscreen display market by segmenting the market based on touchscreen type, component, and end-use industry. In terms of touchscreen type, the market has been segregated into resistive, capacitive, surface acoustic wave (SAW), infrared, and others (including optical imaging and NFI). Based on component, the market has been classified into hardware and software. The hardware segment has been sub-divided into display, touch sensor, and controller. Based on end-use industry, the market has been classified into oil & gas, chemical, food & beverages, mining & metal, automotive, and others (including rubber, plastics, and paper & pulp). The report provides detailed, region-wise breakdown of the global industrial touchscreen display market and categorizes it at various levels, thereby providing valuable insights at micro and macro levels.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/industrial-touchscreen-display-market-global-industry-analysis-size-share-growth-trends-and-forecast-2018-2026-report.html/toc

The report highlights competition scenario in the global industrial touchscreen display market, thereby ranking all major players according to their geographic presence and key recent developments. The insights for the global industrial touchscreen display market is a result of TMR’s extensive primary interviews, secondary research, and in-house expert panel reviews. Market estimates have been analyzed by considering the impact of different economic, political, social, legal, and technological factors.

On the basis of country, the industrial touchscreen display in North America has been segmented into Canada, the U.S., and Rest of North America. Furthermore, the Europe market has been divided into France, Germany, the U.K., and Rest of Europe. The industrial touchscreen display market in Asia Pacific has been segmented into China, Japan, India, South Korea, and Rest of Asia Pacific. The Middle East & Africa market covers GCC, South Africa, and Rest of Middle East & Africa. Similarly, the market in South America includes Brazil and Rest of South America. The report provides all strategic information required to understand the industrial touchscreen display market. Also, the report provides insights into touchscreen type, component, and end-user industry segments of the market in various geographical regions mentioned above.

Global Industrial Touchscreen Display Market: Research Methodology

The research methodology is a perfect combination of primary research, secondary research, and expert panel reviews. Secondary sources such as annual reports, company websites, SEC filings and investor presentations, national government documents, internal and external proprietary databases, statistical databases, relevant patent and regulatory databases, market reports, government publications, statistical databases, World Bank database, and market white papers are usually referred.

Primary research involves telephonic interviews, e-mail interactions, and face-to-face interviews conducted for obtaining detailed and unbiased reviews on the industrial touchscreen display market across geographies. Primary interviews are usually conducted on an ongoing basis with market experts and participants in order to obtain the latest market insights and validate the existing data and analysis. Primary interviews offer new information on important factors such as market trends, market size, competition landscape, and growth trends. These factors help validate and strengthen secondary research findings. Moreover, the data collected and analyzed from secondary and primary research is again discussed and examined by TMR’s expert panel.

Global Industrial Touchscreen Display Market: Competition Dynamics

The research study includes profiles of leading companies operating in the global industrial touchscreen display market. Market players have been profiled in terms of attributes such as company overview, financial overview, business strategies, and recent developments. Parameters such as investments in and spending on industrial touchscreen displays and developments by major market players have been tracked. Some of the key players operating in the industrial touchscreen display market are Advantech Co., Ltd, Cypress Semiconductor Corporation, Dell, Inc., B&R Industrial Automation GmbH, Elo Touch Solutions, Inc., Fujitsu Ltd., Hewlett Packard Enterprise, LG Electronics, Panasonic Corporation, Planar Systems, Kontron AG, Schneider Electric S.E., Siemens AG, Beckhoff Automation GmbH & Co. KG, Captec Ltd., and American Industrial Systems.

The global industrial touchscreen display market has been segmented as follows:

Global Industrial Touchscreen Display Market, by Touchscreen Type

    Resistive
    Capacitive
    Surface Acoustic Wave
    Infrared
    Others (Including Optical Imaging and NFI)

Global Industrial Touchscreen Display Market, by Component

    Hardware
        Display
        Touch Sensor
        Controller
    Software

Global Industrial Touchscreen Display Market, by End-use Industry

    Oil & Gas
    Chemical
    Food & Beverages
    Mining & Metal
    Automotive
    Others (Including Rubber, Plastics, and Paper & Pulp)

Global Industrial Touchscreen Display Market, by Geography

    North America
        U.S.
        Canada
        Rest of North America
    Europe
        Germany
        U.K.
        France
        Rest of Europe
    Asia Pacific
        China
        Japan
        India
        South Korea
        Rest of Asia Pacific

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2080995

    Middle East & Africa (MEA)
        GCC
        South Africa
        Rest of MEA
    South America
        Brazil
        Rest of South America

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Worldwide Technology : Global Antibacterial Drugs Market 2019 to 2022

ResearchMoz presents professional and in-depth study of "Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance".

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=970729

This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.

In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-antibacterial-drugs-market-to-2022-vaccines-retain-market-prominence-while-pipeline-offers-innovative-approaches-to-tackling-antimicrobial-resistance-report.html/toc

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:
  - How big is the antibiotic pipeline?
  - How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
  - How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
  - Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
  - Which molecular targets are most popular in the current pipeline?
  - How many late-stage products are active against drug-resistant bacteria?
  - What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
  - Which of the leading companies are expected to have the highest share of the market by 2022?
  - Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
  - Which companies rely heavily of revenues derived from antibacterial drugs?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the antibacterial drug market in the context of the overall pipeline and current market landscape. It also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include pneumonia, MRSA, sepsis and tuberculosis.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=970729

- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for antibacterial therapies.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Professional Growth : Colorectal Cancer - Heat Map and Analysis 2019

ResearchMoz presents professional and in-depth study of "Colorectal Cancer - Heat Map and Analysis".

Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=984797

It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.

The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient’s quality of life.

Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/colorectal-cancer-heat-map-and-analysis-report.html/toc

Scope

    How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
    What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?
    How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?
    How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?
    Are future product approvals likely to affect the treatment algorithm significantly?

Reasons to buy

    Understand the current clinical landscape by considering the treatment options available for earlyand late-stage disease.
    Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
    Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
    Understand the relative strengths and weaknesses of the studies used to gather these data.
    Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
    Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Table of Contents

1 Table of Contents
1 Table of Contents 2

2 Introduction 3
2.1 Report Guidance 6

3 Marketed Products 7
3.1 Early-Stage Adjuvant Therapy 7
3.2 Advanced (Unresectable or Metastatic) Therapy 8
3.2.1 Chemotherapy 9
3.2.2 Targeted Therapies 10

4 Pipeline Products 13
4.1 Changes to Early-Stage Adjuvant Therapies, 2017–2022 13
4.2 Changes to Advanced (Unresectable or Metastatic) Therapies, 2017–2022 13
4.2.1 Changes to Chemotherapies, 2017–2022 13
4.2.2 Changes to Targeted Therapies, 2017–2022 14

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=984797

5 Appendix 17
5.1 Abbreviations 17
5.2 References 18
5.3 Research Methodology 21
5.4 Contact Us 21
5.5 Disclaimer 21

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Latest Trend : Cardiovascular Disorders Drug Development Pipeline Review, 2019

ResearchMoz presents professional and in-depth study of "Cardiovascular Disorders Drug Development Pipeline Review, 2017".

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1049123

As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/cardiovascular-disorders-drug-development-pipeline-review-2017-report.html/toc

Scope

    Which companies are the most active within the pipeline for CVD.
    Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.
    To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.
    What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

    Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
    Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
    Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
    Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 15
Introduction 18
Cardiovascular Disorders Report Coverage 18
Hypertension Overview 18
Dyslipidemia Overview 18
Thromboembolism Overview 18
Heart Failure Overview 18
Therapeutics Development 20
Hypertension 20
Dyslipidemia 22
Thromboembolism 24
Heart Failure 26
Therapeutics under Development by Companies 31
Hypertension 31
Dyslipidemia 35
Thromboembolism 39
Heart Failure 40

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1049123

Therapeutics under Investigation by Universities/Institutes 47
Hypertension 47
Dyslipidemia 49
Thromboembolism 50
Heart Failure 50
Pipeline Products Glance 52
Hypertension 52

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Global Outlook : Respiratory Complications Therapeutics Market 2019 to 2022

ResearchMoz presents professional and in-depth study of "Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market".

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The causes of respiratory disorders vary significantly between indications, with potential causes including infection, vascular damage or dysfunction, aging, environmental stressors such as pollution, and genetic predisposition.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1049124

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that treat the disease symptoms rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in cystic fibrosis (CF), where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The chronic obstructive pulmonary disease (COPD) and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

The respiratory therapy area contains numerous primary indications, including asthma, COPD, CF and idiopathic pulmonary fibrosis (IPF), which have large prevalent populations. In addition, there are many secondary respiratory conditions that have smaller prevalent populations yet significant unmet clinical needs. This report focuses on these secondary respiratory conditions, particularly pneumonia, respiratory syncytial virus (RSV), pulmonary arterial hypertension (PAH) and tuberculosis (TB).

A major cause of secondary respiratory disease is infections caused by bacteria or viruses. Bacterial infections, such as pneumonia and TB, and viral infections, such as RSV, cause infection of the lungs. The immune system response to these infections causes inflammation that interferes with the ability of the lungs to function. Cardiovascular problems also represent another major cause of respiratory complications. PAH in particular represents a profound risk factor for cardiovascular events in the pulmonary vascular system, including pulmonary embolism.

Overall, there are 843 products in active development in the respiratory complications pipeline. However, this total constitutes many individual indications, most of which are typically relatively small in terms of the number of pipeline products in development. Pneumonia, TB, RSV and PAH are the secondary conditions with the largest development pipelines.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-respiratory-complications-therapeutics-market-report.html/toc

Scope

    The respiratory complications market already contains commercially successful products.
    Which classes of drug dominate the market?
    What additional benefits have newly approved therapies brought to the market.
    The respiratory complications pipeline is large, with significant diversity in terms of molecule types and targets.
    Which molecular targets appear most frequently in the pipeline?
    What are the commercial prospects for the most promising late-stage pipeline products.
    The respiratory complications market is forecast to grow from $21.8 billion in 2015 to $30.2 billion in 2022, at a compound annual growth rate of 4.7%.
    Which products are forecast to drive this substantial growth?
    Will generic competition have a significant impact on the market over the forecast period.
    The company landscape is becoming increasingly competitive.
    What are the leading companies in terms of market share?
    Which companies are forecast to experience the greatest growth in market share.
    What are the drivers of growth for key companies in the market?
    How dependent are the key companies on this disease cluster for revenue.

Reasons to buy

This report will allow you to -

    Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which include pneumonia, TB, RSV and PAH.
    Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
    Analyze the respiratory complications pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
    Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1049124

    Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory complications products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
    Identify commercial opportunities in the respiratory complications deals landscape by analyzing trends in licensing and co-development deals.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Market Technologies : Global Biosimilar Pipeline and Market Prospects 2019

ResearchMoz presents professional and in-depth study of "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design".

GBI Research’s latest report, ""Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design"" provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities and the strategies being implemented to overcome them.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1063794

This report also assesses the state of the biosimilar R&D and commercial landscape through multilevel analytics that include data split by therapy area, stage of development, molecular target, clinical trials and company. Global revenue forecasts to 2022 for biosimilars with strong market potential, both in development and in the market, are provided.

The complex requirements of manufacturing biological drugs also apply to biosimilars, and these have been a significant barrier to the further expansion of the biosimilars market. A key challenge has been the knowledge gap under which biosimilars are developed, which arises from the fact that innovator product information remains proprietary and biosimilar manufacturers must adopt a reverse engineering process. Our new study assesses this and other significant manufacturing challenges, and how strategies based on quality initiatives and risk management can help address these issues.

Data analyses from our study show there will be enormous commercial opportunities for biosimilar developers over the coming years, given the number of high-revenue-generating biologics that will go off patent before 2020, and promising revenue forecasts for biosimilars in late-stage development. Information leveraged from our robust industry-leading database highlights a diverse number of biosimilars in the pipeline for a wide range of therapy areas, with several of these in the later stages of development. Case studies showcasing strategies adopted by leading pharmaceutical companies to compete in the biosimilars market are also provided.

Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. Our study details current biosimilar regulatory frameworks and guidelines implemented in the US, Europe, Japan and China, recent updates regarding the key issue of interchangeability, and case studies of successful biosimilar approvals in recent years.

GBI Research conducted extensive research efforts in order to provide a comprehensive view of the global biosimilar market. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-biosimilar-pipeline-and-market-prospects-addressing-production-complexities-through-risk-management-and-quality-by-design-report.html/toc

Scope

Global biosimilar pipeline in 2017

    What is the distribution of pipeline biosimilars by stage of development?
    Which are the therapy areas set to benefit the most from biosimilar drugs in development?
    In biosimilar development, what are the most common molecular targets for key therapy areas?
    How many companies are currently involved in biosimilar drug development, which are the most active and what is the level of specialization across the development landscape?

Global biosimilar clinical trials in 2017

    What was the volume of biosimilar clinical trials from 2006 to 2016, by therapy area and stage of development?
    What is the average biosimilar clinical trial size and duration across different stages of development, and across the immunology and oncology therapy areas?
    How much revenue will promising biosimilar drugs in the market, and in development, record to 2022?
    What are the key factors driving growth in the global biosimilars market?
    How important are the cost saving opportunities for national healthcare budgets?
    How much will biosimilar manufacturers benefit from the biologic drugs patent cliff?
    How does legislation regarding biosimilar interchangeability differ among key geographical markets?
    What are the factors restraining the growth of global biosimilar market?
    How do manufacturing challenges affect the market?
    What are the legal issues impacting the biosimilar market?
    How are competition and patient recruitment issues slowing growth in the market?
    What are the regulatory pathways for biosimilars in the US, Europe, Japan and China?

Manufacturing processes for biosimilar drugs

    How does molecular weight and complexity pose a challenge to biosimilar production?
    What is the impact of environmental factors on production complexity?
    How significant is the knowledge gap in the process of manufacturing a biosimilar drug?
    What are the best practice guidelines and strategies to overcome production complexities? 
    How do development timelines and costs differ between biologics and biosimilars?
    What is the impact of immunogenicity in the production process?

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1063794

Reasons to buy

This report will allow you to -

    Gain insightful analyses and comprehensive understanding of the global biosimilar R&D and commercial landscape
    Assess biosimilar production processes, key issues and ways to mitigate development risk
    Understand the most important driving and restraining forces in the global biosimilars market
    Learn about biosimilar strategies being adopted by leading pharmaceutical companies.
    Understand the future outlook and prospects for biosimilar drugs

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Detailed Analysis : Neurodegenerative Disorders Drug Development Pipeline Review, 2019

ResearchMoz presents professional and in-depth study of "Neurodegenerative Disorders Drug Development Pipeline Review, 2017".

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1064532

Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

    Which companies are the most active within the pipeline for neurodegenerative disorders?
    Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
    To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
    What are the most important R&D milestones and data publications to have happened in this disease area?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/neurodegenerative-disorders-drug-development-pipeline-review-2017-report.html/toc

Reasons to buy

    Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
    Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
    Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
    Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 25
Introduction 27
Neurodegenerative Disorders Report Coverage 27
Alzheimer's Disease Overview 27
Amyotrophic Lateral Sclerosis Overview 27
Huntington Disease Overview 27
Multiple Sclerosis Overview 27
Parkinson's Disease Overview 27
Therapeutics Development 28
Alzheimer's Disease 28
Amyotrophic Lateral Sclerosis 30
Huntington Disease 32
Multiple Sclerosis 34
Parkinson's Disease 36

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1064532

Therapeutics under Development by Companies 38
Alzheimer's Disease 38
Amyotrophic Lateral Sclerosis 50
Huntington Disease 55
Multiple Sclerosis 58
Parkinson's Disease 68

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Business Strategy : Global Cancer Supportive Care Therapeutics Market 2019 to 2022

ResearchMoz presents professional and in-depth study of "Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets".

The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. Instead of extending a patient’s life expectancy, the emphasis is on improving overall quality of life. The key indications covered in this report are cancer pain, oral mucositis, chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV) and bone metastasis.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1065936

These indications are not only distressing for patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise.

The majority of indications targeted by cancer supportive care products are the direct result of a patient receiving chemotherapy in an attempt to cure their cancer or relieve symptoms. It is often the case that the most effective chemotherapy regimens result in the most severe symptoms. This increases the need for cancer supportive care products, which can improve patient outcomes by providing greater tolerance to the most effective regimens. Bone metastasis and most forms of cancer pain are not caused by chemotherapy or cancer treatment, and are instead often a symptom of the cancer itself, occurring in a high proportion of cancer patients.

The level of unmet need within the cancer supportive care therapy area varies between indications. CIN and CINV both already have treatment regimens that can significantly decrease the incidence rate. However, the level of unmet need for CIA, cancer pain, oral mucositis and bone metastasis is high, with treatment focusing heavily on alleviating the symptoms instead of treating the underlying cause.

There are 245 products in active development in the cancer supportive care pipeline, but this includes products in development for smaller and less commercially significant indications. There are 169 products in active development for the key indication examined in this report, giving an average of 28 products per indication, the majority of which are at an early stage of development.

Scope

The cancer supportive care market already contains some commercially successful products.

    Which classes of drug dominate the market?
    Which indication is the most commercially successful?
    How will commercially successful drugs perform over the forecast period?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-cancer-supportive-care-therapeutics-market-to-2022-patent-expirations-create-opportunities-for-biosimilars-in-the-chemotherapy-induced-anemia-and-neutropenia-markets-report.html/toc

The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.

    Which molecular targets appear most frequently in the pipeline?
    What are the commercial prospects for the most promising late-stage pipeline products?

The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.

    Which products are forecast to drive growth?
    Will generic and biosimilar competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

    What are the leading companies in terms of market share?
    Which companies are forecast to experience the greatest growth in market share?
    What are the drivers of growth for key companies in the market?
    How dependent are the key companies on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

    Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report
    Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
    Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
    Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1065936

    Identify the leading companies in the market, in terms of market share and growth. Company analysis illustrates how dependent the key companies in the market are on revenue derived from cancer supportive care products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
    Identify commercial opportunities in the cancer supportive care deals landscape by analyzing trends in licensing and co-development deals.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Business Opportunities : Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2019

ResearchMoz presents professional and in-depth study of "Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017".

This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1070458

These key indications are all common side effects of cancer chemotherapy treatment, and result in a substantial reduction in the patient’s quality of life. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Chemotherapy-induced neutropenia is another very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. Chemotherapy-induced anemia symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems.

The size of these pipelines ranges from 16 in chemotherapy-induced anemia to 41 in chemotherapy-induced neutropenia and CIPN. In CINV and CIPN, there is a relatively diverse range of targets which are being studied, although most of these targets are neurotransmitter receptors. On the other hand, the pipelines for chemotherapy-induced neutropenia and anemia are far more limited in the range of molecular targets being studied.

Scope

    Which companies are the most active within the pipeline for toxicology therapeutics?
    Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
    To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
    What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?

Reasons to buy

    Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
    Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
    Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
    Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

View Complete TOC with tables & Figures @ https://www.researchmoz.us/toxicology-cluster-chemotherapy-related-toxicity-drug-development-pipeline-review-2017-report.html/toc

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 9

Introduction 10
Toxicology Cluster Chemotherapy Related Toxicity Report Coverage 10
Chemotherapy Induced Nausea and Vomiting – Overview 10
Chemotherapy Induced Neutropenia – Overview 10
Chemotherapy Induced Anemia – Overview 10
Chemotherapy Induced Peripheral Neuropathy – Overview 10
Therapeutics Development 11
Chemotherapy Induced Nausea and Vomiting 11
Chemotherapy Induced Neutropenia 15
Chemotherapy Induced Anemia 20

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1070458

Chemotherapy Induced Peripheral Neuropathy 23
Therapeutics Assessment 30
Chemotherapy Induced Nausea and Vomiting 30
Chemotherapy Induced Neutropenia 37
Chemotherapy Induced Anemia 45

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Market Study : Global Mobile Health (mHealth) Technologies Market Prospects - Featuring Expert Panel Views from Industry Survey 2019

ResearchMoz presents professional and in-depth study of "Mobile Health (mHealth) Technologies: Global Market Prospects - Featuring Expert Panel Views from Industry Survey 2017".

GBI Research’s latest report Mobile Health (mHealth) Technologies: Global Market Prospects – Featuring Expert Panel Views from Industry Survey 2017 provides a comprehensive analysis of the mHealth landscape. GBI Research conducted an extensive industry survey of 65 experts from the pharmaceutical, medical devices, healthcare and healthcare IT industries – including organizations that already implement mHealth solutions and services, and those that do not.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1144778

The survey gathered experience and opinion on the use of mHealth, and insights on key trends for the present and future use of these technologies, particularly within the pharmaceutical industry. The findings from the survey and results from secondary research efforts have been amalgamated with GBI’s own analytical views to provide an assessment that is comprehensive in outlook.

mHealth is a branch of eHealth, and commonly defined as the use of modern information and communication technologies to meet needs of citizens, patients, healthcare professionals, healthcare providers as well as policy markets. It can have a significant impact on consumers and on all aspects of the pharmaceutical and healthcare sector, and companies are making large investments to leverage these technologies more effectively. mHealth technologies are already a reality in both developed and developing countries, and their uptake is expected to significantly increase in the near future, particularly as the overall healthcare industry continues to shift towards value-based medicine, and due to the increasing need for more cost-effective means to deliver healthcare and to demonstrate the value and effectiveness of medical treatments.

The report features an overview of mHealth solutions and services and its place within the pharmaceutical industry. It examines the factors driving and necessitating the use of these technologies within this industry, and provides detailed examples of how different solutions could be used to provide direct benefits to pharmaceutical companies, healthcare institutions and patients. There is also an analysis of the main challenges surrounding these technologies, as well as case studies of how companies are already implementing mHealth, and deal with some of the challenges. Finally, based on the totality of the survey results and research, strategic recommendations are provided for the effective implementation of new mHealth initiatives.

The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including results from key geographical markets. The survey examined key issues, such the areas where pharmaceutical organizations are currently utilizing mHealth; where they believe it can have the most impact; the main barriers to uptake and driving factors; the likelihood of increasing investment within the next five years; and the overall attitude towards the use of these technologies within the pharmaceutical industry.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/mobile-health-mhealth-technologies-global-market-prospects-featuring-expert-panel-views-from-industry-survey-2017-report.html/toc

GBI Research conducted extensive research to provide a comprehensive view of mHealth solutions and services. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising areas in the market and exploit key business opportunities.

Scope

    What are mHealth technologies. What is their place within the pharmaceutical industry.
    How prevalent is the use of mHealth technologies in the pharmaceutical, healthcare and healthcare IT industries.
    What are the main driving factors necessitating the use of mHealth. What is the relative importance of these factors.
    What are the commercial benefits that the use of mHealth solutions and services can provide across the pharmaceutical value chain.
    In which areas are organizations currently using mHealth, and where do they feel it will have the most impact in the next five years.
    What are the main challenges associated with mHealth technologies. What is the relative importance of these factors across key geographical markets. For the organizations that do not yet utilize mHealth solutions, what specific reasons have led to this decision.
    What is the likelihood that organizations that already use mHealth will increase their investment within the next five years. Will those that do not currently invest in the technology begin doing so over this period.
    How can mHealth initiatives be effectively implemented within an organization.
    What is the overall opinion of industry experts on the use of mHealth technologies.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1144778

Reasons To Buy

    Gain insightful analyses and comprehensive understanding of mHealth technologies
    Understand the key drivers necessitating the use of mHealth and the main barriers to implementation
    Understand the views of 65 different organizations within the industry on mHealth
    Assess the most relevant uses of mHealth solutions and services within your company, and effective ways of implementing mHealth initiatives

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Market Scope : Innovation and Clinical Trial Tracking Factbook 2019 : An Assessment of the Pharmaceutical Pipeline

ResearchMoz presents professional and in-depth study of "Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline".

GBI Research’s latest report: “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the 25,522 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1144779

This pipeline is also benchmarked against its size across each segment compared to 2015 and 2016, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005–2008, when the proportion was relatively high.

Scope

    What is the current size and composition of the pharmaceutical industry pipeline and how has it changed in the last two years? What can we learn from this?
    The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/innovation-and-clinical-trial-tracking-factbook-2017-an-assessment-of-the-pharmaceutical-pipeline-report.html/toc

    What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
    What factors have been driving the increasing number of first-in-class product approvals over recent decades?
    Historically, what has the risk of clinical trial attrition been across each therapy area and molecule type in the pharmaceutical industry? How long have their associated clinical trials been and how many patients, on average, were recruited?

Reasons To Buy

    Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
    Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one’s own strategic positioning against this backdrop
    Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
    Make key decisions about the role of innovation within one’s own pipeline portfolio
    Understand and benchmark the risk of attrition, clinical trial duration and size across the pharmaceutical industry

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Increasing Cost of Drug Development 7
2.2 Most Drugs Fail to Recuperate R&D Costs 8
2.3 Contracting Life Cycles for Approved Products 9
2.4 The Case for First-in-Class Pharmaceutical Innovation 10
2.5 Conclusion 13

3 Assessment of the Pharmaceutical Industry Pipeline 14
3.1 Pipeline and Clinical Trials Landscape by Therapy Area 14
3.2 Pipeline by Stage of Development 19
3.3 Pipeline by Molecule Type 22
3.4 Key Therapy Areas by Indication 26
3.4.1 Oncology 26
3.4.2 Infectious Diseases 27
3.4.3 Central Nervous System 29
3.4.4 Immunology 32
3.5 Conclusion 33

4 Assessment of Innovation in the Pharmaceutical Industry Pipeline 34
4.1 First-in-Class Innovation by Stage of Development 36
4.2 Key Therapy Areas by Indication 37
4.2.1 Oncology 37
4.2.2 Infectious Diseases 40
4.2.3 Central Nervous System 43
4.2.4 Immunology 46
4.3 Conclusion 48

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1144779

5 Assessment of the Pharmaceutical Industry Clinical Trial Landscape 49
5.1 Clinical Trial Attrition Rates 49
5.1.1 Therapy area 50
5.1.2 Molecule Type 54
5.2 Clinical Trial Duration 57
5.2.1 Therapy Area 58
5.2.2 Molecule Type 61

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/